Document is current

Article History

Received: 20 June 2024

Accepted: 11 November 2024

First Online: 26 November 2024

Competing interests

: S.P.: consulting or advisory role for Novartis, Pfizer, SeaGen, AstraZeneca, Daiichi Sankyo, and Pierre Fabre. Speakers’ Bureau for: Novartis, Lilly, Roche, Gilead Sciences, Pfizer, Daiichi Sankyo/AstraZeneca and research funding (to institute) from Roche, outside of the submitted work. ESF: The authors declare no potential conflicts of interest. G.V.: speaker’s fee from MSD, Pfizer, GSK and Pierre Fabre, has held an advisory role with AstraZeneca and received consultant fees from Reveal Genomics. J.S.: Advisory role: Lilly, Novartis, AstraZeneca, Gilead. Speakers’ Bureau for: Novartis, Roche, Pfizer and Daiichi Sankyo. Travel and accommodation for Roche and Novartis. A.P.: The authors declare no potential conflicts of interest. X.G.: Astra Zeneca (travel), Novartis (speaker), Pierre Fabre (speaker). B.J.: Invited speaker (Novartis, Lilly, Roche, Daiichi Sankyo), Advisory Board (Esteve), travel fees for congresses (Daiichi Sankyo). M.M.: The authors declare no potential conflicts of interest. PP: travel support from MSD, Lilly, Pharmamar, GSK; speakers AstraZeneca, GSK, Clovis, Pfizer. T.P.: Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers’ bureaus) from Astra Zeneca, Novartis, Pfizer, Veracyte and Lilly; Consulting Fees (e.g., advisory boards) from Novartis. E.A.: Advisory role: Novartis, Pfizer, Lilly, Gilead, AstraZeneca, Exact Science. Investigation grant: Pfizer. L.V.: The authors declare no potential conflicts of interest. S.C.: The authors declare no potential conflicts of interest. JMFC: The authors declare no potential conflicts of interest. PG: The authors declare no potential conflicts of interest. A.P.: Personal financial interests: Lecture fees (AstraZeneca, Roche, Pfizer, Novartis, Daiichi Sankyo), Advisory role/consultancy (Roche, Pfizer, Novartis, Guardant Health, Peptomyc & Lilly), Leadership role (Reveal Genomics, SL; Pangea, 1TrialSP sc). Institutional financial interests: Contracted research (AstraZeneca, Boehringer, Novartis, Roche, Nanostring, Sysmex Europa GmbH, Medica Scientia Innovation Research SL, Pfizer). Leadership roles: Executive boards (Pangaea, 1TrialSP, SL), Patronage committee (Actitud Frente al Cáncer Foundation), co-founder and CSO (Reveal Genomics, SL). E.C.: Personal financial interest: Advisory Board (AstraZeneca, Daiichi Sankyo, Lilly, MSD, Novartis, Pfizer, Roche, Gilead, Seagen), Invited Speaker (Lilly, Pfizer, Roche, Seagen), Speakers Bureau (Roche), Travel accommodation (AstraZeneca). No financial interest: principal investigator for TATEN trial (sponsor SOLTI group), Patricia 2 trial (sponsor: SOLTI Group), Prometeo 2 trial (sponsor: SOLTI Group), ATREZZO trial (sponsor: SOLTI Group), Scientific Evaluator at Instituto de Salud Carlos III, advisory role (Spanish Government Academic Research Platform) and SOLTI Cooperative Group, Member of Board of Directors, Non-profit organization dedicated to breast cancer research.